MX347429B - Cristales de múltiples componentes que comprenden dasatinib y formadores de cocristales seleccionados. - Google Patents
Cristales de múltiples componentes que comprenden dasatinib y formadores de cocristales seleccionados.Info
- Publication number
- MX347429B MX347429B MX2014015433A MX2014015433A MX347429B MX 347429 B MX347429 B MX 347429B MX 2014015433 A MX2014015433 A MX 2014015433A MX 2014015433 A MX2014015433 A MX 2014015433A MX 347429 B MX347429 B MX 347429B
- Authority
- MX
- Mexico
- Prior art keywords
- dasatinib
- cocrystal formers
- multicomponent crystals
- multicomponent
- gallate
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title abstract 3
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 title abstract 2
- 239000002067 L01XE06 - Dasatinib Substances 0.000 title abstract 2
- 229960002448 dasatinib Drugs 0.000 title abstract 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 abstract 2
- VFPFQHQNJCMNBZ-UHFFFAOYSA-N ethyl gallate Chemical compound CCOC(=O)C1=CC(O)=C(O)C(O)=C1 VFPFQHQNJCMNBZ-UHFFFAOYSA-N 0.000 abstract 2
- FBSFWRHWHYMIOG-UHFFFAOYSA-N methyl 3,4,5-trihydroxybenzoate Chemical compound COC(=O)C1=CC(O)=C(O)C(O)=C1 FBSFWRHWHYMIOG-UHFFFAOYSA-N 0.000 abstract 2
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 abstract 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 abstract 1
- 239000004262 Ethyl gallate Substances 0.000 abstract 1
- YIKYNHJUKRTCJL-UHFFFAOYSA-N Ethyl maltol Chemical compound CCC=1OC=CC(=O)C=1O YIKYNHJUKRTCJL-UHFFFAOYSA-N 0.000 abstract 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 235000019277 ethyl gallate Nutrition 0.000 abstract 1
- 229940093503 ethyl maltol Drugs 0.000 abstract 1
- 229960004873 levomenthol Drugs 0.000 abstract 1
- 229940041616 menthol Drugs 0.000 abstract 1
- IBKQQKPQRYUGBJ-UHFFFAOYSA-N methyl gallate Natural products CC(=O)C1=CC(O)=C(O)C(O)=C1 IBKQQKPQRYUGBJ-UHFFFAOYSA-N 0.000 abstract 1
- 235000010388 propyl gallate Nutrition 0.000 abstract 1
- 239000000473 propyl gallate Substances 0.000 abstract 1
- 229940075579 propyl gallate Drugs 0.000 abstract 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 abstract 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 abstract 1
- 235000012141 vanillin Nutrition 0.000 abstract 1
- 229940117960 vanillin Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C35/02—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring monocyclic
- C07C35/08—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring monocyclic containing a six-membered rings
- C07C35/12—Menthol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
- C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
- C07C47/58—Vanillin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
- C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
- C07D309/40—Oxygen atoms attached in positions 3 and 4, e.g. maltol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a un sistema cristalino de componentes múltiples (co-cristal) que comprende un compuesto de la fórmula I (INN: Dasatinib) y un segundo compuesto seleccionado de metil-4-hidroxibenzoato, o nicotinamida, o galato de etilo, o galato de metilo, o galato de propilo, o etil maltol o vainillina, o mentol, o (1R,2S,5R)-(-), así como a un proceso para obtenerlo.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261659997P | 2012-06-15 | 2012-06-15 | |
EP12172172 | 2012-06-15 | ||
PCT/IB2013/054832 WO2013186726A2 (en) | 2012-06-15 | 2013-06-13 | Multicomponent crystals comprising dasatinib and selected cocrystal formers |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014015433A MX2014015433A (es) | 2015-09-16 |
MX347429B true MX347429B (es) | 2017-04-26 |
Family
ID=49758817
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014015433A MX347429B (es) | 2012-06-15 | 2013-06-13 | Cristales de múltiples componentes que comprenden dasatinib y formadores de cocristales seleccionados. |
Country Status (12)
Country | Link |
---|---|
US (1) | US9340536B2 (es) |
EP (1) | EP2861589B1 (es) |
JP (1) | JP6211072B2 (es) |
KR (1) | KR20150020683A (es) |
CN (1) | CN104379582A (es) |
AU (1) | AU2013276138B2 (es) |
BR (1) | BR112014031292A2 (es) |
CA (1) | CA2876539A1 (es) |
ES (1) | ES2637829T3 (es) |
MX (1) | MX347429B (es) |
RU (1) | RU2650524C2 (es) |
WO (1) | WO2013186726A2 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150020683A (ko) | 2012-06-15 | 2015-02-26 | 바스프 에스이 | 다사티닙 및 선택된 공-결정 형성제를 포함하는 다성분 결정 |
US9221789B2 (en) | 2012-06-22 | 2015-12-29 | Basf Se | Multicomponent crystals comprising imatinib mesilate and selected co-crystal formers |
US9290452B2 (en) | 2012-08-06 | 2016-03-22 | Basf Se | Multicomponent crystalline system comprising deferasirox and isonicotinamide and a process for the preparation thereof |
EP2909191B1 (en) | 2012-10-19 | 2019-03-20 | Basf Se | Multicomponent crystalline system comprising nilotinib and selected co-crystal formers |
AU2014295144B2 (en) | 2013-07-25 | 2017-06-15 | Basf Se | Salts of Dasatinib in crystalline form |
RU2655435C2 (ru) | 2013-07-25 | 2018-05-29 | Басф Се | Соли дасатиниба в аморфной форме |
CA2950485A1 (en) | 2014-06-30 | 2016-01-07 | Basf Se | Multicomponent crystals of dasatinib with menthol or vanillin |
IT201700006157A1 (it) * | 2017-01-20 | 2018-07-20 | Cerbios Pharma Sa | Co-cristalli di un composto antitumorale |
IT201700006145A1 (it) | 2017-01-20 | 2018-07-20 | Cerbios Pharma Sa | Co-cristallo di un composto antitumorale |
AU2018297710A1 (en) | 2017-07-07 | 2020-02-27 | Biocon Limited | Polymorphic forms of dasatinib |
JP7166754B2 (ja) | 2017-11-22 | 2022-11-08 | 沢井製薬株式会社 | ダサチニブ無水物含有製剤 |
WO2019209908A1 (en) | 2018-04-25 | 2019-10-31 | Johnson Matthey Public Limited Company | Crystalline forms of dasatinib |
JP7409696B2 (ja) | 2018-06-15 | 2024-01-09 | ハンダ ファーマシューティカルズ インコーポレイテッド | キナーゼ阻害剤の塩およびその組成物 |
US10799459B1 (en) | 2019-05-17 | 2020-10-13 | Xspray Microparticles Ab | Rapidly disintegrating solid oral dosage forms containing dasatinib |
CN112028896A (zh) * | 2020-10-14 | 2020-12-04 | 奥锐特药业(天津)有限公司 | 阿卡替尼的新晶型及其制备方法 |
CN114805046B (zh) * | 2022-04-25 | 2023-05-12 | 东华理工大学 | 香草醛与酰胺类化合物的共晶结构及其制备方法 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2391550T3 (es) * | 1999-04-15 | 2012-11-27 | Bristol-Myers Squibb Company | Inhibidores cíclicos de la proteína tirosina quinasa |
WO2004078163A2 (en) * | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
TWI338004B (en) * | 2004-02-06 | 2011-03-01 | Bristol Myers Squibb Co | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
US7491725B2 (en) | 2004-02-06 | 2009-02-17 | Bristol-Myers Squibb Company | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
WO2006027795A1 (en) * | 2004-09-09 | 2006-03-16 | Natco Pharma Limited | Novel phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase |
AR054438A1 (es) * | 2005-04-15 | 2007-06-27 | Kudos Pharm Ltd | Inhibidores de adn -pk |
CN101268072A (zh) * | 2005-04-15 | 2008-09-17 | 库多斯药物有限公司 | Dna-pk抑制剂 |
WO2007035874A1 (en) | 2005-09-21 | 2007-03-29 | Bristol-Myers Squibb Company | Oral administration of n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide and salts thereof |
KR20080074963A (ko) * | 2005-11-10 | 2008-08-13 | 쉐링 코포레이션 | 단백질 키나제 억제제로서의 이미다조피라진 |
AU2006315334B2 (en) * | 2005-11-16 | 2011-05-19 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
EP2111401B1 (en) * | 2006-12-20 | 2011-02-16 | Bayer HealthCare, LLC | 4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl) phenyl]-1h-pyrazol-5-yl } carbamoyl)-amino]-3-fluorophenoxy} -n-methylpyridine-2-carboxamide as well as prodrugs and salts thereof for the treatment of cancer |
PL2508523T5 (pl) * | 2007-10-23 | 2020-08-10 | Teva Pharmaceutical Industries Ltd. | Odmiany polimorficzne dasatynibu i sposób ich wytwarzania |
CN104530052A (zh) * | 2008-06-10 | 2015-04-22 | 普莱希科公司 | 用于激酶调节的5h-吡咯[2,3-b]吡嗪衍生物和其适应症 |
WO2010062715A2 (en) * | 2008-11-03 | 2010-06-03 | Teva Pharmaceutical Industries Ltd. | Polymorphs of dasatinib and process for preparation thereof |
WO2010067374A2 (en) * | 2008-12-08 | 2010-06-17 | Hetero Research Foundation | Polymorphs of dasatinib |
CZ20098A3 (cs) * | 2009-01-13 | 2010-07-21 | Zentiva, K.S. | Lékové formy inhibitoru tyrosinových kináz |
WO2010112411A1 (en) * | 2009-03-30 | 2010-10-07 | Tibotec Pharmaceuticals | Co-crystal of etravirine and nicotinamide |
CN102770434A (zh) * | 2009-12-03 | 2012-11-07 | 阿斯利康(瑞典)有限公司 | ***并[4,5-d]嘧啶血小板聚集抑制剂的共晶体 |
CA2806820A1 (en) * | 2010-07-30 | 2012-02-02 | Ranbaxy Laboratories Limited | N-methylformamide solvate of dasatinib |
US9249108B2 (en) | 2010-11-22 | 2016-02-02 | Basf Se | Multicomponent system of rosuvastatin calcium salt and sorbitol |
CN102030745B (zh) | 2010-11-26 | 2012-05-09 | 江苏先声药物研究有限公司 | Dasatinib溶剂合物及其制备方法 |
CA2832343A1 (en) | 2011-04-18 | 2012-10-26 | Basf Se | Multicomponent crystalline system of rosuvastatin calcium salt and vanillin |
WO2013014604A1 (en) | 2011-07-26 | 2013-01-31 | Basf Se | Multicomponent crystalline system of ezetimibe and proline |
US20150087657A1 (en) | 2011-12-06 | 2015-03-26 | Basf Se | Multicomponent crystalline system of voriconazole with fumaric acid |
US8796481B2 (en) | 2011-12-30 | 2014-08-05 | Basf Se | Crystalline solvate and non-solvated forms of 6,6′-[[3,3′,5,5′-tetrakis(1,1-dimethylethyl)-[1,1′biphenyl]-2,2′-diyl]bis(oxy)]bis-dibenzo [d,f] [1,3,2]-dioxaphosphepine |
WO2013098370A1 (en) | 2011-12-30 | 2013-07-04 | Basf Se | Crystalline solvate and non-solvated forms of 6,6'-[[3,3',5,5'-tetrakis(1,1-dimethylethyl)-[1,1'-biphenyl]-2,2'-diyl]bis(oxy)]bis-dibenzo [d,f] [1,3,2]-dioxaphosphepine |
WO2013143927A1 (en) | 2012-03-29 | 2013-10-03 | Basf Se | Co-crystals of dicamba and a co-crystal former b |
WO2013174694A1 (en) | 2012-05-25 | 2013-11-28 | Basf Se | Crystalline form b of 1,5-dimethyl-6-thioxo-3-(2,2,7-trifluoro-3-oxo-4-(prop-2-ynyl)-3,4-dihydro-2h-benzo[b][1,4]oxazin-6-yl)-1,3,5-triazinane-2,4-dione |
UA117100C2 (uk) | 2012-05-25 | 2018-06-25 | Басф Се | КРИСТАЛІЧНА ФОРМА A 1,5-ДИМЕТИЛ-6-ТІОКСО-3-(2,2,7-ТРИФТОР-3-ОКСО-4-(ПРОП-2-ІНІЛ)-3,4-ДИГІДРО-2H-БЕНЗО[b][1,4]ОКСАЗИН-6-ІЛ)-1,3,5-ТРИАЗИНАН-2,4-ДІОНУ |
KR20150020683A (ko) | 2012-06-15 | 2015-02-26 | 바스프 에스이 | 다사티닙 및 선택된 공-결정 형성제를 포함하는 다성분 결정 |
-
2013
- 2013-06-13 KR KR20157000673A patent/KR20150020683A/ko not_active Application Discontinuation
- 2013-06-13 BR BR112014031292A patent/BR112014031292A2/pt not_active Application Discontinuation
- 2013-06-13 WO PCT/IB2013/054832 patent/WO2013186726A2/en active Application Filing
- 2013-06-13 ES ES13804937.4T patent/ES2637829T3/es active Active
- 2013-06-13 AU AU2013276138A patent/AU2013276138B2/en not_active Ceased
- 2013-06-13 EP EP13804937.4A patent/EP2861589B1/en not_active Not-in-force
- 2013-06-13 MX MX2014015433A patent/MX347429B/es active IP Right Grant
- 2013-06-13 JP JP2015516734A patent/JP6211072B2/ja not_active Expired - Fee Related
- 2013-06-13 US US14/406,339 patent/US9340536B2/en not_active Expired - Fee Related
- 2013-06-13 CA CA2876539A patent/CA2876539A1/en not_active Abandoned
- 2013-06-13 RU RU2015100280A patent/RU2650524C2/ru not_active IP Right Cessation
- 2013-06-13 CN CN201380031458.7A patent/CN104379582A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
RU2650524C2 (ru) | 2018-04-16 |
WO2013186726A2 (en) | 2013-12-19 |
MX2014015433A (es) | 2015-09-16 |
US9340536B2 (en) | 2016-05-17 |
JP6211072B2 (ja) | 2017-10-11 |
CN104379582A (zh) | 2015-02-25 |
ES2637829T3 (es) | 2017-10-17 |
EP2861589A2 (en) | 2015-04-22 |
AU2013276138B2 (en) | 2017-02-23 |
JP2015525227A (ja) | 2015-09-03 |
RU2015100280A (ru) | 2016-08-10 |
EP2861589A4 (en) | 2016-03-02 |
CA2876539A1 (en) | 2013-12-19 |
BR112014031292A2 (pt) | 2017-06-27 |
WO2013186726A3 (en) | 2014-02-20 |
AU2013276138A1 (en) | 2015-01-22 |
US20150133463A1 (en) | 2015-05-14 |
KR20150020683A (ko) | 2015-02-26 |
EP2861589B1 (en) | 2017-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2014015433A (es) | Cristales de múltiples componentes que comprenden dasatinib y formadores de cocristales seleccionados. | |
PH12015501226A1 (en) | Crystalline 6,7-unsaturated-7-carbamoyl morphinane derivative, and method for producing the same | |
EA201500173A1 (ru) | Фунгицидные композиции | |
MY162411A (en) | Crystalline forms of a macrolide, and uses therefor | |
CA2830549C (en) | Methods and compositions for preparing noribogaine from voacangine | |
WO2015008218A3 (en) | Process for the preparation of suvorexant and intermediates useful in the synthesis of suvorexant | |
WO2013093931A3 (en) | Novel prodrugs of phenolic drugs | |
FR2975990B1 (fr) | Procede de preparation d'un compose organique fluore | |
WO2014017938A3 (en) | Process for the synthesis of substituted urea compounds | |
WO2012131707A3 (en) | Crystalline form of bortezomib, preparation method and pharmaceutical composition there f | |
FR2984333B1 (fr) | Procede de preparation d'un melange-maitre en phase liquide. | |
WO2014159794A3 (en) | Bicyclo [2.2.1] acid gpr120 modulators | |
TN2013000354A1 (en) | Synthesis of 2-carboxamide cycloamino urea derivatives | |
NZ627473A (en) | Aryloxyacetamide compound and pesticide | |
WO2014207567A3 (en) | Process for the preparation of abiraterone and intermediates thereof | |
EP2883870B8 (en) | Method for producing 1,4-benzoxazine compound | |
IN2014MN00971A (es) | ||
MX364529B (es) | Nuevos ligandos del receptor de estrógeno. | |
PH12014501367A1 (en) | Processes for making magnolol and derivatives thereof | |
CY1114704T1 (el) | Κρυσταλλικη μορφη δ του αλατος αργινινης της περινδοπριλης, μεθοδος παρασκευης της και φαρμακευτικες συνθεσεις οι οποιες την περιεχουν | |
WO2013072938A3 (en) | Process for the preparation of roflumilast | |
WO2014195977A3 (en) | Novel polymorphs of vismodegib | |
WO2014030173A3 (en) | Improved process for preparation of atazanavir bisulfate | |
MX2014012822A (es) | Proceso para elaborar derivados de naftiridina. | |
BR112013015903A2 (pt) | polimorfo cristalino, processo para preparar um polimorfo, composição farmacêutica, forma purificada do polimorfo, uso de um polimorfo, processo para preparar um composto, e, composto. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |